Please login to the form below

Not currently logged in
Email:
Password:

Orexigen cuts jobs

Orexigen Therapeutics has cut 40 per cent of its workforce following the recent refusal to approve obesity drug Contrave in the US

Orexigen Therapeutics has laid off 40 per cent of its workforce following the US Food and Drug Administration's (FDA) recent refusal to approve Contrave (naltrexone/bupropion), the obesity drug the company is developing with Takeda Pharmaceutical.

Orexigen said it was cutting 23 employees in the wake of the complete response letter it received on January 31 stating that the drug is not approvable until the company conducts an additional large-scale clinical study designed to measure cardiovascular effects.

The job cuts, which are expected to generate cost savings of about $5m a year, will result in a one-time charge for Orexigen of $2.6m related to employee termination costs.

Orexigen said it continues to believe in the potential of Contrave, which is its lead product candidate, and will discuss the drug's future with the FDA.

Meanwhile, the Obesity Society, a scientific society dedicated to the study of obesity, issued a statement taking the FDA to task for its handling of the Contrave marketing application and painting a pessimistic view of the drug's future.

"The economics of (the cardiovascular) trial make it extremely unlikely that it can be done, effectively ending hopes for approval, despite the earlier recommendation of the FDA's own advisory panel to approve the drug for use prior to a study," according to a statement from the Society.

Dr Jennifer Lovejoy, the Society's president, added: "The FDA seems to expect that any obesity medication must be as free of side effects as tap water. This is an unrealistic standard and one to which medications for other diseases are not held."

She continued, saying the Society "will be working with several other professional societies in the coming weeks to meet with FDA and Congressional leaders and discuss improvements to the process of reviewing obesity medications."

The FDA's decision on Contrave went against the recommendation of its Endocrinologic and Metabolic Drugs Advisory Committee, which voted at a meeting in December to recommend that the agency require a post-approval cardiovascular study of Contrave but determined that the current data is adequate for approval.

10th February 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

brian smith science of the deal
The science of the deal
Business development is more like child-raising than you might think...
The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...

Infographics